The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study.
 
Lewis Fady Nasr
No Relationships to Disclose
 
Nicholas James Short
Honoraria - Amgen
Consulting or Advisory Role - Amgen; AstraZeneca; NGM Biopharmaceuticals; Novartis; Pfizer; Takeda
Research Funding - Astellas Pharma; Stemline Therapeutics; Takeda
 
Jayastu Senapati
No Relationships to Disclose
 
Yesid Alvarado Valero
No Relationships to Disclose
 
Nitin Jain
Honoraria - Abbvie/Genentech; Adaptive Biotechnologies; Adaptive Biotechnologies; ADC Therapeutics; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pfizer; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb/Celgene; CareDX; Cellectis; Ipsen; Janssen; MEI Pharma; MingSight; NovalGen; Pharmacyclics; Precision Biosciences; SERVIER; TG Therapeutics
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics (Inst); Aprea Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Celgene (Inst); Cellectis (Inst); CRC Oncology (Inst); Dialectic Therapeutics (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); KisoJi Biotechnology (Inst); Kite, a Gilead company (Inst); Loxo/Lilly (Inst); Medisix Therapeutics (Inst); Medisix Therapeutics (Inst); MingSight (Inst); Newave Pharmaceutical (Inst); NovalGen (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Precision Biosciences (Inst); Sana Biotechnology (Inst); SERVIER (Inst); Takeda (Inst); TransThera Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - CRLF2 Bispecific antibody
 
Marina Konopleva
Honoraria - Abbvie; Amgen; Amgen; Forty Seven; Genentech; KisoJi Biotechnology; Roche; Stemline Therapeutics
Consulting or Advisory Role - AbbVie; Amgen; Forty Seven; Genentech/Roche; Janssen; KisoJi Biotechnology; KisoJi Biotechnology; Roche; Stemline Therapeutics
Research Funding - Abbvie (Inst); Ablynx (Inst); Agios (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Forty Seven (Inst); Genentech (Inst); Lilly (Inst); Roche (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Eli LIlly- Research Funding; Issued/ Licensed; Novartis- PENDING; Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities); Reata pharmaceutical - Research Funding- (Issued, Licensed, Royalities)
 
Walid Macaron
No Relationships to Disclose
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor
 
Courtney Denton Dinardo
Stock and Other Ownership Interests - Notable Labs
Honoraria - Abbvie; Astellas Pharma; Bristol Myers Squibb Foundation; Cleave Biosciences; Foghorn Therapeutics; Genentech/Abbvie; Genmab; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Novartis; Schrodinger; SERVIER
Consulting or Advisory Role - Abbvie; Agios; Celgene; GlaxoSmithKline
Research Funding - Abbvie; Astex Pharmaceuticals; Celgene; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Jazz Pharmaceuticals; Loxo/Lilly; SERVIER
 
Koji Sasaki
Honoraria - Amgen; Chugai Pharma; Otsuka
Consulting or Advisory Role - Novartis; Pfizer; Takeda
Research Funding - Novartis
Travel, Accommodations, Expenses - Otsuka
 
Alessandra Ferrajoli
Consulting or Advisory Role - AstraZeneca; Giants of Cancer Care; Janssen Oncology
Patents, Royalties, Other Intellectual Property - Acerta Pharma; BeiGene; Celgene
 
Cedric Christophe Nasnas
No Relationships to Disclose
 
Marianne Zoghbi
No Relationships to Disclose
 
Jovitta Jacob
No Relationships to Disclose
 
Ejiroghene Mayor
No Relationships to Disclose
 
Anna Milton
No Relationships to Disclose
 
Christopher Loiselle
No Relationships to Disclose
 
Rebecca Garris
No Relationships to Disclose
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; Ascentage Pharma Group; Astellas Pharma; AstraZeneca/MedImmune; Daiichih-Sankyo (Inst); Immunogen (Inst); Ipsen; Jazz Pharmaceuticals (Inst); KAHR Medical; Novartis; Pfizer; Precision Biosciences; Shenzhen Target Rx; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie
Research Funding - Abbvie (Inst); Amgen (Inst); Ascentage Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Ascentage Pharma Group; Pfizer; Takeda